biostudies-literaturePorcari AMinistero della SaluteItalian Ministry of Health2952-2960https://www.ebi.ac.uk/biostudies/studies/S-EPMC12803573biostudies-literatureUnknown27(12)<h4>Aims</h4>Tafamidis reshaped the treatment paradigm in transthyretin amyloid cardiomyopathy (ATTR-CM) based on a phase-3 randomized controlled trial, but real-world data on its use remain limited. This study aimed to assess in a large, contemporary, real-world cohort of patients with wild-type ATTR-CM (ATTRwt-CM) (i) the clinical phenotype of patients receiving tafamidis, and (ii) the association of tafamidis with survival using propensity-matched observational data.<h4>Methods and results</h4>Data of patients diagnosed with ATTRwt-CM (January 2017 to June 2023) from 19 Italian centres were analysed. A propensity score (PS) reflecting the likelihood of being treated with tafamidis for each patient was determined using four variables that were significantly different among the two groupsEuropean journal of heart failureClinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.PMC12803573RC-2024-2 789 983RC‐2024‐2 789 983Foti GBonacchi GSanna GDLofiego CMarazia SMilani PGentile PBiagini EMonda EDi Marco MCantone ASinagra GLonghi SGardini ECanepa MSturda FBartolotti MMusumeci BCipriani AMerlo MRuotolo IPerfetto FTomasoni DMusca FDriussi MPalladini GDi Bella GLimongelli GMerlini GSerenelli MCarigi SColio FD'Elia ETini GVergaro GSena GMarini MMetra MCappelli FDe Michieli LZanoletti MPorcari AAimo AEmdin MPerlini SSinigiani GVagnarelli FImazio MPozzan MfalseClinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.<h4>Aims</h4>Tafamidis reshaped the treatment paradigm in transthyretin amyloid cardiomyopathy (ATTR-CM) based on a phase-3 randomized controlled trial, but real-world data on its use remain limited. This study aimed to assess in a large, contemporary, real-world cohort of patients with wild-type ATTR-CM (ATTRwt-CM) (i) the clinical phenotype of patients receiving tafamidis, and (ii) the association of tafamidis with survival using propensity-matched observational data.<h4>Methods and results</h4>Data of patients diagnosed with ATTRwt-CM (January 2017 to June 2023) from 19 Italian centres were analysed. A propensity score (PS) reflecting the likelihood of being treated with tafamidis for each patient was determined using four variables that were significantly different among the two groups2025-01-01T00:00:00Z2025 Dec2026-07-15T13:19:50.402Z2026-07-05T03:08:38.71ZS-EPMC128035734131715610.1002/ejhf.70071